CanSino Biologics Inc. (CANSINOBIO) filed its Monthly Return for the period ended 31 July 2026, confirming stability across both its Hong Kong-listed H shares and Shanghai STAR Market A shares.

Authorised and Issued Share Capital • Authorised share capital stood unchanged at RMB 247.04 million, split between 132.67 million H shares and 114.37 million A shares, each with a par value of RMB 1. • Issued share counts matched authorised levels, with no new shares issued, cancelled or repurchased during the month. Treasury share balances remained nil.

Public Float Compliance • The company affirmed compliance with Hong Kong Main Board Rule 13.32D, maintaining at least 5% public float for its H-share class.

Equity Incentive Plans • H-Share Options: 860,000 options under the “2025 Core Management H Share Option Scheme” remained outstanding; no exercises or cancellations occurred in July. • A-Share Restricted Stock: Up to 2.05 million A shares may still be issued under the “2025 Restricted A Share Incentive Scheme,” with no grants or transfers executed during the month.

Capital Structure Summary (31 July 2026) • Total authorised / issued shares: 247.04 million • Treasury shares: 0 • Potential dilution from outstanding H-share options: 0.35% of current issued H-share base. • Additional potential issuance under A-share restricted scheme: 1.80% of current issued A-share base.

Management Confirmation Joint Company Secretary Jin Cui submitted the return, which indicates no other outstanding convertibles, warrants or share repurchase activities for the reporting month.